News

Valsartan Cut Cardiovascular Events by 45%


 

“In hypertension, getting the patients to take their medication is the most important thing you can do. I always say that any drug I can get the patient to take is the right medication. A lot of us like to use ARBs because they have minimal side effects,” said Dr. Bove, a cardiologist at Temple University, Philadelphia.

The Kyoto Heart Study was funded by Kyoto Prefectural University. Dr. Matsubara and Dr. Ruschitzka reported having no financial conflicts of interest regarding their presentations.

The 45% decrease with valsartan was driven by risk reductions of 55% for stroke and 49% for angina.

Source DR. MATSUBARA

Pages

Recommended Reading

Studies Need More Hispanics to Unravel Paradox
MDedge Internal Medicine
Sertraline Falls Short for Depressed HF Patients
MDedge Internal Medicine
Depressed Patients May Not Follow Hypertension Regimen
MDedge Internal Medicine
Depression Worsens Impact of CVD Risk Factors in Women
MDedge Internal Medicine
Study Supports Air Travel/VTE Link
MDedge Internal Medicine
Mutations Related to Thrombophilia Implicated as Risk Factors for VTE
MDedge Internal Medicine
VTE Risk Rises in Tall Men, but Not In Tall Women
MDedge Internal Medicine
Pulmonary Embolism Rises With BMI in Women : 'There is a strong, independent, positive, linear association between BMI and incident PE.'
MDedge Internal Medicine
High HDL Linked to Thromboembolism Risk in Women
MDedge Internal Medicine
Treatment-Resistant Hypertension Common
MDedge Internal Medicine